VCM
AVBP icon

Versant Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Versant Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7K Hold
423
– – ﹤0.01% 2083
2026
Q1 		$9.76K Buy
423
+10
+2% +$226 ﹤0.01% 2151
2025
Q4 		$8.31K Buy
413
+223
+117% +$4.64K ﹤0.01% 2073
2025
Q3 		$3.51K Sell
190
-186
-49% -$3.65K ﹤0.01% 2316
2025
Q2 		$8.19K Buy
+376
New +$7.81K ﹤0.01% 1976

Other funds holding AVBP

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Versant Capital Management's AVBP Position: Q2 2026 in Review

Versant Capital Management held its ArriVent BioPharma (AVBP) position steady in Q2 2026 at 423 shares worth $14.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2083.

Versant Capital Management first reported a position in AVBP in Q2 2025 and has held it in 5 quarters since. 9 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Versant Capital Management held 423 shares of ArriVent BioPharma worth $14.7K as of Q2 2026.
  • Versant Capital Management left its ArriVent BioPharma share count unchanged in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2083 holding.
  • Versant Capital Management first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 5 quarters since.
  • 9 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.